MedTrace Logo

Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients

NCT01197794 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1144

Last updated 2013-11-06

Study results available
· View outcomes & findings →

Summary

The study will assess the efficacy, safety and tolerability of AZD1981 compared to non-active compound in asthmatic patients.

Conditions

  • Asthma Patients

Interventions

DRUG

AZD1981

AZD1981 twice daily

DRUG

AZD1981

AZD1981 once daily

DRUG

Placebo

Placebo to match AZD1981

Sponsors & Collaborators

Principal Investigators

  • Chris O'Brien, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States
  • Argentina
  • Brazil
  • Japan
  • Mexico
  • Romania
  • Russia
  • Slovakia
  • South Africa
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01197794 on ClinicalTrials.gov